Practical guidance for turning scientific evidence into usable data
Each paper takes one question discovery and informatics teams face when working with patents, papers, and bioactivity data, and sets out what has to stay intact for the answer to hold up.
Start with the question in front of you
From patents and papers to program-ready drug discovery data
Five requirements for keeping structures, bioactivity, assay context, and provenance intact from the source document to a schema a program can use.
Read the paper → Comparing activity valuesCan these IC50 values actually be compared?
A 2024 ChEMBL32 analysis found that 64% of paired IC50s differed by more than 0.3 log units. Why assay context has to stay attached to the value.
Read the paper → Reading a competitor filingTheir patent is your starting point
Use a competitor filing to see where they invested, what the data supports, and where the claim ends before the next design, filing, partner, or challenge decision.
Read the paper →Bring us the scientific question, schema, or slice
Describe what your team needs to determine, structure, or acquire. Excelra will recommend the most efficient starting point and scope the corresponding pilot.